POLYMORPHISM OF THE ARYLAMINE-N-ACETYLTRANSFERASE GENE IN ENDOMETRIOSIS PATIENTS IN THE REPUBLIC OF BASHKORTOSTAN
Iskhakova GM1,*, Abazova EF2, Viktorova TV1, Kudakaeva LR1
*Corresponding Author: Dr. Gulnaz M. Iskhakova, Department of ?, Bashkir State Medical University, 450000 Ufa, Lenina St. 3, Russia; Tel.: +007-347-273-5875; Fax: +007-347-272-3751; E-mail: iskhakov_vr@ rambler.ru
page: 55

RESULTS AND DISCUSSION

Of the endometriosis patients, 48.0% were from 41 to 50 years old, 87.0% suffered from algodysmenorrhea, 82.4% from chronic pelvic pain, 49.0% had problems with their menstrual cycles and 44.0% were infertile. The pre­vailing nosologic forms were: focal womb endometriosis (32.9%), diffusive womb endometriosis (25.5%) and extensive endometriosis (17.0%). Some 91.5% of the patients suffered from accompanying diseases, with ane­mia with cardiovascular system diseases and gastrointes­tinal diseases being present in 24.2 and 27.3%, respec­tively. A combination of endometriosis and womb myoma was preset in 39.1%, and 23.7% had chronic inflammatory diseases of womb and uterine appendages. The patients were prescribed dufaston or danazol. This treatment could be considered effective, if the pain syndrome had abated, the menstrual cycle had become normal, there had been positive dynamics of the results of ultrasound examination and hysteroscopy. Fifty-four patients received hormonal treatment, of whom 32 (59.3%) gave a positive result.

      There were more slow acetylators (S) among the endo­metriosis patients [77.4% as compared with 62.2% in the control group; λ2 = 8.276; p = 0.0210, odds ratio (OR) = 2.08) (Table 2). The distribution of the allele frequencies of the NAT2 gene in endometriosis patients and in con­trols is presented in Figure 1.

      The prevailing allele in the control group was NAT2*5 (39.4%) vs. 30.6% in the endometriosis group (λ= 3.8625; p = 0.0494). This NAT2*5 is the most wide­spread, occurring in 44.0 to 47.0% of the Caucasian popu­lation [4]. Nat2*4 without any signs of mutation was pres­ent in 11.9% of endometriosis patients and in 19.5% of the controls (λ= 5.2189; p = 0.0228; OR = 1.8323). This suggests that, NAT2*4 and NAT2*5 are protective alleles. NAT2*7 was present in 31.1% of endometriosis patients (λ2 = 31.3488, p = 0.0005; OR = 3.8972). In the European population, its frequency is 1.0 to 3.0%, but in the popula­tion of the Volgo-Ural region its frequency is 10.2% [4,22]. In our control group, its frequency was 10.4%. We found that NAT2*7 is a marker for endometriosis. The index of OR was 3.9 [confidence interval (CI) = 2.3352-6.5370]. NAT2*6 was found in 26.6% of the endo­me­triosis patients and in 30.7% of the controls. The distribu­tion of the NAT2 gene genotypes in endometriosis patients and in controls is presented in the Table 3.

      The number of genotypes in the endometriosis patients was 16 vs. 14 in the controls. There protective genotypes NAT2*4/*5, NAT2*4/*6 and NAT2*5/*6 had a total fre­quency of 22.6% in the endometriosis group and 53.8% in the controls. Genotypes NAT2*6/*6/*7, NAT2*6/*7/*7, NAT2*7/*7 were found only in endometriosis patients, with a total frequency of 13.7%. Genotypes of high risk such as NAT2*5/*6/*7, NAT2*5/*7/*7, NAT2*6/*6/*7, NAT2*6/*7/*7 and NAT2*7/*7 had a total frequency of 34.3% in the endometriosis group and 5.0% in the con­trols. There were 43.1% of slow acetylators with more than two mutant alleles in the endometriosis patients, but only 10.9% in the control group (λ2 = 28.1181; p = 0.0005). The index of OR was 6.19.

      The very slow acetylators prevailed in the patients with extensive endometriosis, focal womb endometriosis and ovary endometriosis (58.8, 54.5 and 50.0%, respec­tively) but were less frequent in those with endometriosis of the neck of the womb (30.8%). Slow acetylators were more frequent among those with diffusive womb endo­metriosis and endometriosis of the neck of the womb (44.0 and 46.1%, respectively). The frequency of R carriers in patients with endometriosis and infertility in anamnesis was twice as high as that among the other patients (11.6 and 5.9%, respectively).

      We have studied the effectiveness of hormonal treat­ment in relation to the NAT2 gene polymorphism in endo­metriosis patients. There prevailed in individuals with the genotypes that contained more than one mutant allele in the group of patients sensitive to pharmacotherapy (78.8%). In individuals with the NAT2*4/4 gene, the treat­ment was effective in only 3.0% of cases, and was not effective in 13.6% of cases.

      These results indicate that inactivation of xenobiotics, including drugs, occur in endometriosis patients with the NAT2*4/4 genotype, whereas individuals with mutant alleles in the genotype benefit from slower inactivation of drugs and this may stipulate for higher effectiveness of the therapy. They also indicate that unfavorable NAT2 alleles have a role in the pathogenesis of endometriosis and influ­ence the effectiveness of therapy.

 

Table 2. Distribution of the phenotype frequencies

 

 

n

Frequency of Phenotypes

According to the NAT2 Gene

 

 

R

Absolute (%)

S

Absolute (%)

Patients

102

23 (22.6)

79 (77.4)

Controls

119

45 (37.8)

74 (62.2)

c2; p

5.314; 0.022

 

 

 

   NAT2/Kpnl

 

 NAT2/Tagl

 

 NAT2/BamHI

 

Figure 1. Distribution of the NAT2 alleles in endometriosis patients.

 

 

Table 3. Polymorphism of the NAT2 gene

 

 

Patients (n = 102)

Controls (n = 119)

NAT2 Genotype

Absolute

%

Absolute

%

*4/*4

6

5.9

5

4.2

*4/*5

7

6.9

20

16.8

*4/*6

4

3.9

14

11.8

*4/*7

6

5.9

5

4.2

*5/*5

3

2.9

12

10.1

*5/*5/*6

4

3.9

2

1.7

*5/*5/*7

6

5.9

3

2.5

*5/*6

12

11.8

30

25.2

*5/*6/*6

3

2.9

2

1.7

*5/*6/*7

16

15.7

5

4.2

*5/*7

7

6.9

7

5.9

*5/*7/*7

5

4.9

1

0.8

*6/*6

0

0.0

9

7.6

*6/*6/*7

5

4.9

0

0.0

*6/*7

9

8.8

4

3.4

*6/*7/*7

5

4.9

0

0.0

*7/*7

4

3.9

0

0.0

Alleles

4

29

11.7

49

19.5

5

76

30.6

99

39.4

6

66

26.6

77

30.7

7

77

31.1

26

10.4

 
 
 
 
 

Figure 2. The distribution of the frequencies of NAT2 genotypes in endometriosis patients




Number 26
Number 26 VOL. 26(2), 2023 All in one
Number 26
VOL. 26(2), 2023
Number 26
VOL. 26, 2023 Supplement
Number 26
VOL. 26(1), 2023
Number 25
VOL. 25(2), 2022
Number 25
VOL. 25 (1), 2022
Number 24
VOL. 24(2), 2021
Number 24
VOL. 24(1), 2021
Number 23
VOL. 23(2), 2020
Number 22
VOL. 22(2), 2019
Number 22
VOL. 22(1), 2019
Number 22
VOL. 22, 2019 Supplement
Number 21
VOL. 21(2), 2018
Number 21
VOL. 21 (1), 2018
Number 21
VOL. 21, 2018 Supplement
Number 20
VOL. 20 (2), 2017
Number 20
VOL. 20 (1), 2017
Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006